Identifying Fibromyalgia-Associated Symptoms and Conditions from a Clinical Perspective: A Step Toward Evaluating Healthcare Resource Utilization in Fibromyalgia

Pain Practice

Volumn 10, Issue 6, 2010, Pages 520-529

  Silverman, Stuart L ^a   Harnett, James ^b   Zlateva, Gergana ^b   Mardekian, Jack ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b PFIZER INC   (United States)

Author keywords

Fibromyalgia; Patient management; Physician perspective; Symptoms

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIMIGRAINE AGENT; ATOMOXETINE; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CITALOPRAM; CORTICOSTEROID; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; DOXEPIN; DULOXETINE; IMIPRAMINE; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PAROXETINE; PEMOLINE; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SIMETHICONE; SPASMOLYTIC AGENT; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE; UNINDEXED DRUG; VENLAFAXINE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AMNESIA; ANESTHESIST; ANXIETY DISORDER; ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COMPUTER PROGRAM; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; FATIGUE; FEMALE; FIBROMYALGIA; HEADACHE; HEALTH CARE SURVEY; HEALTH CARE UTILIZATION; HUMAN; INSOMNIA; IRRITABLE COLON; MALE; MEMORY; MUSCLE WEAKNESS; MYALGIA; NERVOUSNESS; PHYSICIAN; PRESCRIPTION; PRIMARY MEDICAL CARE; PSYCHIATRIST; QUESTIONNAIRE; RHEUMATOLOGY; SLEEP DISORDER; SYMPTOM; TREATMENT PLANNING;

EID: 78049458747     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2010.00383.x     Document Type: Article

References (29)

1. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58:26-35.
2. Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 1994;37:1593-1601.
3. Abeles AM, Pillinger MH, Solitar BM, Abeles M. Narrative review: the pathophysiology of fibromyalgia. Ann Intern Med. 2007;146:726-734.
4. Wood PB, Schweinhardt P, Jaeger E, et al. Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci. 2007;25:3576-3582.
5. Collado A, Valdes M, Bargallo N, et al. Increased glutamate compounds in the brain of patients with fibromyalgia: a MR spectroscopy study [abstract. Ann Rheum Dis. 2009;68(suppl 3):117.
6. Harris RE. Glutamate levels in the insula and pain perception in fibromyalgia [abstract]. Ann Rheum Dis. 2009;68(suppl 3):25.
7. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160-172.
8. Bennett RM, Jones J, Turk DC, Matallana L. An internet survey of 2, 596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8:27.
9. Arnold LM, Crofford LJ, Mease PJ, et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns. 2008;73:114-120.
10. Bernard AL, Prince A, Edsall P. Quality of life issues for fibromyalgia patients. Arthritis Care Res. 2000;13:42-50.
11. Verbunt JA, Pernot DH, Smeets RJ. Disability and quality of life in patients with fibromyalgia. Health Qual Life Outcomes. 2008;6:8.
12. White KP, Speechley M, Harth M, Ostbye T. Comparing self-reported function and work disability in 100 community cases of fibromyalgia syndrome versus controls in London, Ontario. The London Fibromyalgia Epidemiology Study. Arthritis Rheum. 1999;42:76-83.
13. Silverman S, Dukes EM, Johnston SS, Brandenburg NA, Sadosky A, Huse DM. The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis. Curr Med Res Opin. 2009;25:829-840.
14. Berger A, Sadosky A, Dukes E, Martin S, Edelsberg J, Oster G. Characteristics and patterns of healthcare utilization of patients with fibromyalgia in general practitioner settings in Germany. Curr Med Res Opin. 2008;24:2489-2499.
15. Annemans L, Wessely S, Spaepen E, et al. Health economic consequences related to the diagnosis of fibromyalgia syndrome. Arthritis Rheum. 2008;58:895-902.
16. Sicras-Mainar A, Rejas J, Navarro R, et al. Treating patients with fibromyalgia in primary care settings under routine medical practice: a claim database cost and burden of illness study. Arthritis Res Ther. 2009;11.
17. Perrot S, Dickenson AH, Bennett RM. Fibromyalgia: harmonizing science with clinical practice considerations. Pain Pract. 2008;8:177-189.
18. Wolfe F, Rasker JJ. The Symptom Intensity Scale, fibromyalgia, and the meaning of fibromyalgia-like symptoms. J Rheumatol. 2006;33:2291-2299.
19. Wilke WS. New developments in the diagnosis of fibromyalgia syndrome: say goodbye to tender point? Cleve Clin J Med. 2009;76:345-352.
20. Boomershine CS, Crofford LJ. A symptom-based approach to pharmacologic management of fibromyalgia. Nat Rev Rheumatol. 2009;5:191-199.
21. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol. 1991;18:728-733.
22. Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Claxton AJ. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol. 2003;30:1318-1325.
23. Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Wolfe F. Depression and fibromyalgia: treatment and cost when diagnosed separately or concurrently. J Rheumatol. 2004;31:1621-1629.
24. White LA, Birnbaum HG, Kaltenboeck A, Tang J, Mallett D, Robinson RL. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med. 2008;50:13-24.
25. Silverman S, Sadosky A, Evans C, Yeh Y, Alvir J, Zlateva G. Assessing fibromyalgia severity. Poster presented at World Institute of Pain 5th World Congress, New York, March 13-17, 2009.
26. Mease PJ, Arnold LM, Crofford LJ, et al. Identifying the clinical domains of fibromyalgia: Contributions from clinician and patient delphi exercises. Arthritis Rheum. 2008;59:952-960.
27. Winkelmann A, Perrot S, Schaefer C, et al. What are the costs and consequences of fibormyalgia? Results from a European cross-sectional study [abstract]. Ann Rheum Dis. 2009;68(suppl 3):687.
28. Berger A, Dukes E, Martin S, Edelsberg J, Oster G. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract. 2007;61:1498-1508.
29. Berger A, Martin S, Dukes E, Edelsberg J, Oster G. Patterns of pain-related pharmacotherapy in patients with fibromyalgia. Manag Care Interface. 2008;20:30-38.